ModifiedColorado Rocky Mountain Health PlansPolicy DCP040.11

Miscellaneous Diagnostic Procedures

Defines coverage stance and clinical guidance for selected in-office diagnostic procedures in the dental setting (e.g., HbA1c/glucose screening, caries susceptibility tests, adjunctive mucosal lesion tests, brush biopsy, pulp vitality testing, diagnostic casts, antigen/antibody/molecular testing). Applies to dental providers contracting with the payer.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMiscellaneous Diagnostic Procedures

Policy CodePolicy DCP040.11

Change TypeCode update and content refresh

Effective DateJan 1, 2026

Next Review Date

Key ActionUse updated CDT codes (including newly added D0461) on claims and verify member-specific plan and prior authorization requirements before providing adjunctive diagnostic services.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable CDT codes to reflect annual edits; added D0461.

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

Archived previous policy version DCG040.10.

1new CDT code added (D0461)

Severalitems with insufficient evidence

Supportedpulp vitality tests indicated

Out of scope

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

public health pathogen testing

D0411-D7288referenced CDT codes

Coverage Criteria and Clinical Guidance

inv-01: Pulp vitality testing — Covered when ALL of the following are met

Covered when ALL of the following are met:

Pulp vitality testing - Indications: Pulp vitality tests are indicated when used for traumatic injuries to teeth and for teeth with deep caries or defective restorations.

Thermal or electrical stimulation is used to aid diagnosis of pulpal pathology and need for endodontic therapy.

inv-02: Not indicated / Not supported

Procedures not indicated due to insufficient evidence

Not indicated tests: In-office HbA1c and blood glucose level tests for diagnosing pre-diabetes/diabetes in the dental office setting; caries susceptibility tests; adjunctive pre-diagnostic mucosal lesion detection tests (e.g., autofluorescence, tissue reflectance, chemiluminescence, vital staining, salivary adjuncts); and brush biopsy are not indicated due to insufficient evidence of efficacy or improved health outcomes.

These items are described as not indicated in the policy and may be excluded or require further justification per member benefit documents.

inv-03: Public health pathogen testing — Out of scope

Antigen/antibody/molecular testing scope

Public health pathogen testing: Antigen, antibody, and molecular testing for public health–related pathogens is out of scope for dental providers within the dental office; refer to the Description of Services for service boundaries.

Codes D0604-D0606 are referenced as relating to public health pathogen testing.

inv-04: Coverage and clinical use guidance

Guideline-based stance and recommended clinical actions

Gold-standard diagnostic action: For patients with clinically suspicious oral lesions, perform surgical biopsy and histopathological assessment for diagnosis and staging.

ADA and NCCN guidance specify biopsy as the primary diagnostic step; adjunctive tests should not replace biopsy.

When biopsy not immediately possible: If the patient declines biopsy or access is limited, cytologic testing (brush cytology) may be used temporarily to initiate the diagnostic process and inform need for referral, but a surgical biopsy should be pursued when feasible.

ADA suggests cytologic adjunct only when biopsy is declined or inaccessible and recommends documentation of follow-up actions.

Adjunctive devices (chemiluminescence, autofluorescence, tissue reflectance, vital staining, salivary/blood biomarkers) lack sufficient diagnostic accuracy to replace biopsy; use as adjuncts only and interpret cautiously, ideally by experienced clinicians.

Systematic reviews and Cochrane evidence report variable sensitivity and specificity; none are recommended as replacements for biopsy.

inv-05: Coverage considerations

General informational stance and coverage determiners

General coverage considerations: Coverage determinations require reference to the member-specific benefit plan document; FDA approval or clearance alone is not a basis for coverage. Adjunctive diagnostic devices are informational aids and should not be assumed covered without benefit verification.

Providers should check member benefits, prior authorization requirements, and applicable federal or state mandates.

The policy identifies several chairside tests that are not supported by sufficient evidence for diagnostic use in the dental setting. Specifically, in‑office HbA1c and blood glucose level tests for diagnosing pre‑diabetes/diabetes are described as not indicated when performed in the dental office for diagnostic purposes, and may require referral to primary care for formal diagnostic evaluation. Similarly, caries susceptibility tests (single‑measure microbial or ATP-based assays) and brush biopsy (transepithelial cytology) are described as not indicated due to insufficient evidence of efficacy or improved health outcomes. Finally, adjunctive pre-diagnostic mucosal lesion detection tests (e.g., chemiluminescence, autofluorescence, tissue reflectance, vital staining, salivary adjuncts) are likewise described as not indicated as replacements for standard diagnostic pathways.

When chairside HbA1c screening is performed, the policy notes feasibility evidence but does not endorse dental‑office diagnostic use; instead it supports referral for diagnostic confirmation. For documentation and billing, services characterized as 'not indicated' in this policy (for example codes such as D0411, D0412, D0425, D0431, D7288) may be at risk for denial if billed without clinical justification or applicable plan benefit coverage.

Systematic reviews and evidence syntheses conclude that adjunctive detection devices (chemiluminescence, tissue autofluorescence, ViziLite, VELscope, etc.) and related technologies cannot be recommended as replacements for surgical biopsy and histopathologic assessment. These tools may assist experienced clinicians in identifying lesions but lack the diagnostic accuracy and specificity required to serve as a standalone diagnostic test.

The policy therefore recommends that adjunctive tests be used only as adjuncts to clinical examination and interpreted cautiously by clinicians with appropriate experience; they should not supplant the gold‑standard diagnostic step of surgical biopsy and histologic evaluation.

The policy explicitly states that FDA approval alone is not a basis for coverage. Device regulatory status and FDA product listings are provided for informational purposes only; coverage determinations must be based on clinical evidence and member‑specific benefit documents rather than regulatory clearance or marketing status.

Tests and procedures identified in the policy as not indicated due to insufficient evidence include: in‑office HbA1c and blood glucose level testing for diagnosing pre‑diabetes/diabetes, caries susceptibility tests, adjunctive pre‑diagnostic mucosal lesion detection tests (e.g., chemiluminescence, autofluorescence, tissue reflectance, vital staining, salivary adjuncts), and brush biopsy (transepithelial cytology).

Selected studies highlighted in the policy illustrate limitations of specific adjunctive approaches. Rechmann et al. (2019) found that ATP‑driven bioluminescence (ATP‑B) readings did not differ significantly across clinician‑assessed caries risk levels, indicating poor predictive value for ATP‑B as a standalone caries‑risk tool. Systematic reviews of brush cytology and DNA‑ICM report heterogenous sensitivity and specificity, methodological limitations, and lack of longitudinal evidence to support their use for community screening or as replacements for biopsy. Conversely, systematic reviews of adjunctive optical devices report variable sensitivity and specificity and emphasize that benefits are greatest when used by experienced clinicians and not as primary diagnostic tests.

The document does not provide a single consolidated list labeled explicitly as 'not medically necessary.' Instead, it describes multiple procedures and tests as not indicated due to insufficient evidence, and directs that coverage decisions be made with reference to member‑specific benefit documents and clinical evidence.

Coding and Procedure Codes

Referenced CDT Codesmixed

D0411	HbA1c in-office point of service testing.
D0412	Blood glucose level test - in-office using a glucose meter.
D0425	Caries susceptibility tests.
D0431	Adjunctive pre-diagnostic test that aids in detection of mucosal abnormalities including premalignant and malignant lesions, not to include cytology or biopsy procedures.
D0460	Pulp vitality tests.
D0461	Testing for cracked tooth.
D0470	Diagnostic casts.
D0604	Antigen testing for a public health related pathogen, including coronavirus.
D0605	Antibody testing for a public health related pathogen, including coronavirus.
D0606	Molecular testing for a public health related pathogen, including coronavirus.

1–10 of 11

1/2

Updated applicable CDT CodesCPT

D0461

newly added applicable CDT code (policy update)

inv-14: HbA1c referral threshold

Referral threshold>= 5.7%

Source studyGenco et al. field study (2014) used HbA1c >= 5.7% to refer dental patients for diagnostic evaluation

Action after threshold metRefer patient to primary care/physician for diagnostic evaluation of prediabetes/diabetes

inv-15: FDA product lookup guidance (product codes NBL, EAZ, GEE)

FDA product codes to searchNBL, EAZ, GEE

Usage guidanceSearch the FDA device databases by product code or product name at the FDA PMN/PMN or device listing pages as cited for device-specific information

Provider Responsibilities and Billing Guidance

Prior Authorization

Prior Authorization / Benefit Verification

Diagnostic casts (D0470) may be covered when integral to restorative, prosthodontic, or orthodontic treatment planning; however, prior authorization may be required for certain members or benefit plans. Verify member-specific benefits and prior authorization requirements before scheduling or billing.

Prior authorization requirements vary by plan — confirm via payer portal or member-specific benefit document.

Note

FDA Status Informational

FDA clearance or registration status is provided for informational purposes only. FDA approval or device classification does not determine coverage. Coverage decisions are made based on clinical evidence and the member-specific benefit plan.

Examples of devices: Vizilite, VELscope, Identafi; brush biopsy devices such as Orcellex and OralCDX are Class I and may be exempt from premarket notification.

Background and Evidence Summary

This policy summarizes the evidence for several in‑office diagnostic procedures commonly performed in dental settings. It notes that pulp vitality testing remains a supported diagnostic aid for traumatic tooth injuries and for teeth with deep caries or defective restorations, using thermal or electrical stimulation to inform endodontic treatment decisions. By contrast, the policy finds insufficient evidence to support routine diagnostic use of chairside HbA1c/glucose testing, caries susceptibility assays, adjunctive mucosal lesion detection devices, and brush biopsy as replacements for established diagnostic pathways.

The recommendations reflect systematic reviews, randomized and observational studies, and clinical guidelines: adjunctive mucosal detection devices and salivary/biomarker approaches show variable accuracy and are best considered adjuncts; brush cytology and DNA‑ICM suffer from study heterogeneity and lack longitudinal outcome data; and ATP‑B and similar single‑measure microbiological tests are not predictive enough to replace comprehensive caries risk assessment. The policy emphasizes that surgical biopsy with histopathology remains the gold standard for diagnosing suspicious mucosal lesions, and that FDA device listings are informational and do not by themselves determine coverage.

Definitions

inv-29: HbA1c / A1C definition

DefinitionA blood test that measures average blood glucose (blood sugar) control for the past 2 to 3 months.

SynonymHbA1c commonly referred to as A1C

Clinical useUsed in screening contexts described in the policy to identify patients who may require referral for diagnostic evaluation.

inv-30: Diagnostic Cast definition

DefinitionA replica of teeth and adjoining tissues created digitally or by a casting process (e.g., plaster into an impression).

Also calledStudy model

Coding note

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyMiscellaneous Diagnostic Procedures

Policy CodePolicy DCP040.11

Change TypeCode update and content refresh

Effective DateJan 1, 2026

Next Review Date

Key ActionUse updated CDT codes (including newly added D0461) on claims and verify member-specific plan and prior authorization requirements before providing adjunctive diagnostic services.

SourceLink

On This Page

Caries susceptibility testing: ATP-driven bioluminescence (ATP-B) and similar single-measurement microbiological tests demonstrate inconsistent predictive value for caries risk and should not replace comprehensive caries risk assessment.

Primary studies show ATP-B readings did not significantly differ by clinician-assessed risk; CRA remains superior.

HbA1c chairside screening: Chairside HbA1c screening in dental settings can identify patients with dysglycemia; patients with HbA1c >= 5.7% should be referred to primary care for diagnostic evaluation.>= 5.7%

Feasibility studies have shown identification of patients with dysglycemia but referral and follow-up vary by setting.

ContextCodes correspond to caries detection fluorescence devices (NBL), mucosal adjunctive device listings (EAZ), and brush-biopsy device listings (GEE)

Billing Rule

Coding and Benefit Verification

Use current, updated CDT codes when submitting claims. Inclusion of a code in this policy does not guarantee coverage. Always verify that the code set used is the most recent edition and confirm member benefits prior to billing.

Affected codes include D0411, D0412, D0425, D0431, D0460, D0461, D0470, D0604–D0606, D7288 (refer to member plan for applicability).
Confirm coding edits and bundling rules with the payer before claim submission.

Denial Risk

Denial Risk for Non‑Indicated Tests

Tests and procedures that lack clinical indication or sufficient evidence (e.g., in-office HbA1c and blood glucose screening solely for diabetes diagnosis in dental settings; caries susceptibility tests; adjunctive pre-diagnostic mucosal tests; brush biopsy as standalone diagnostic without follow-up) are at risk for denial. Billing without clinical indication or documentation of medical necessity may result in claim denial.

Denial risk applies when performed for screening without indication or when clinical documentation is absent.
Examples: D0411, D0412, D0425, D0431, D7288 — confirm medical necessity and coverage.

Note

Coverage Decisions Not Based Solely on FDA Status

Coverage decisions are not based solely on FDA approval or device registration. Payers evaluate clinical evidence and member-specific benefit plan terms when determining coverage.

FDA listings and device classifications are informational only; clinical utility and benefit plan language govern coverage determinations.

Documentation Required

Clinical Documentation Expectations

Document clinical indications, examination findings, and rationale for testing or procedures in the patient record. For procedures that may be limited or not routinely covered (e.g., diagnostic casts, adjunctive mucosal tests, in‑office glucose testing), include specific clinical justification and planned follow-up.

Clinical documentation should include: presenting complaint, lesion characteristics (size, color, duration), symptoms, prior treatments, and reason for choosing adjunctive test or diagnostic cast.
For presurgical glucose testing, document symptoms or clinical scenario prompting the test and perioperative risk management plan.

Documentation Required

Document Cytology Results and Follow‑up Actions

When cytology (brush biopsy) is used as an interim measure because a patient declines scalpel biopsy or access to biopsy is limited, document the cytology results and the planned follow-up actions. Positive or atypical cytology should prompt biopsy or specialist referral; negative cytology requires periodic reassessment and documentation of monitoring intervals and criteria for biopsy if lesion persists or progresses.

Record test type, date, cytology findings, communication with the patient about limitations of cytology, and explicit follow-up plan (timing of re-evaluation, criteria for biopsy/referral).
Atypical/positive results: document referral or planned biopsy. Negative results: document scheduled surveillance and instructions given to patient.

Note

Reference Member‑Specific Benefit Plan

Always reference the member-specific benefit plan document when deciding coverage — the member-specific plan governs if there is any conflict with this policy or general guidance. Check for applicable federal or state mandates that may affect coverage.

When in doubt, obtain prior authorization or medical necessity review based on the member-specific benefit plan.
UnitedHealthcare (payer) standard plan terms may differ from member-specific benefits; the member document controls.

Note

General Provider Action

Provider action not otherwise specified in this section should follow payer enrollment, billing, and documentation best practices: verify eligibility, obtain authorizations when required, use current CDT codes, and maintain clear clinical records supporting services rendered.

If a requirement is not specified for a procedure, contact the payer for guidance before delivering or billing for services.

Diagnostic casts are represented by CDT code D0470; check plan benefits for prior authorization requirements.

inv-31: Antigen / Antibody definition

AntigenAny substance capable of eliciting an immune response or of binding with an antibody.

AntibodyA substance produced by B lymphocytes in response to a unique antigen.

Scope noteAntigen/antibody/molecular testing for public health–related pathogens is out of scope for dental providers per policy guidance (codes D0604–D0606).

inv-32: Oral cytology / brush biopsy definition

DefinitionMinimally invasive sampling of oral mucosal cells (e.g., brush biopsy or liquid-based cytology) used as an adjunct to assess lesions; not a replacement for surgical biopsy.

Diagnostic performanceCochrane review reports oral cytology sensitivity ~0.90 and specificity ~0.94 (moderate-certainty evidence).

Clinical roleMay be used temporarily when biopsy is declined or inaccessible, but biopsy/referral remains primary diagnostic recommendation.

inv-33: Class I devices definition

DefinitionClass I devices include non-selective and differential culture media testing devices and some brush biopsy devices; these are exempt from premarket notification requirements but manufacturers must register their establishment.

Regulatory implicationClass I status means FDA clearance is not required prior to marketing for certain devices, but registration is required.

Policy noteFDA approval or device classification alone is informational and not a basis for coverage determination.

inv-34: Adjunctive diagnostic devices examples

ExamplesVizilite®, VELscope®, Identafi®

Brush-biopsy examplesOrcellex® and OralCDX® (brush biopsy devices)

PurposeDevices used as adjunctive aids to detect caries or mucosal abnormalities; should not replace biopsy and must be interpreted cautiously.

FDA lookupSearch Product Code EAZ for adjunctive mucosal devices and Product Code GEE for brush-biopsy listings on the FDA site as cited.